The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Hemoptysis Clinical Trial

Official title:

The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01171768
• Other study ID #: 2008-05-043
• Status: Completed
• Phase: N/A
• First received: July 16, 2010
• Last updated: July 20, 2011
• Start date: June 2008
• Est. completion date: December 2010

Study information

• Verified date: July 2011
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

• patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

Exclusion Criteria:

• patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Hemoptysis
• Inflammatory Lung Diseases
• Lung Diseases

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis	We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.	up to 7 days after enrollment	Yes
Secondary	to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia.	We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.	up to 7 days after enrollment	Yes